ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Fractyl Health Inc

Fractyl Health Inc (GUTS)

6.70
-0.02
(-0.30%)
Closed April 27 4:00PM
6.70
0.00
(0.00%)
After Hours: 6:41PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
6.70
Bid
6.60
Ask
6.90
Volume
111,862
6.47 Day's Range 6.88
5.75 52 Week Range 14.50
Market Cap
Previous Close
6.72
Open
6.69
Last Trade
10
@
6.75
Last Trade Time
Financial Volume
$ 738,541
VWAP
6.6023
Average Volume (3m)
375,391
Shares Outstanding
2,095,000
Dividend Yield
-
PE Ratio
-0.15
Earnings Per Share (EPS)
-45
Revenue
120k
Net Profit
-94.27M

About Fractyl Health Inc

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Fractyl Health Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker GUTS. The last closing price for Fractyl Health was $6.72. Over the last year, Fractyl Health shares have traded in a share price range of $ 5.75 to $ 14.50.

Fractyl Health currently has 2,095,000 shares outstanding. The market capitalization of Fractyl Health is $14.02 million. Fractyl Health has a price to earnings ratio (PE ratio) of -0.15.

GUTS Latest News

Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes

BURLINGTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment...

Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Received IDE approval for the Revita® Remain-1 pivotal study for weight maintenance in patients with obesity after discontinuation of GLP-1 Based Drugs Completion of enrollment in pivotal...

Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs

Revita aims to be the first approved therapeutic option for durable weight maintenance after discontinuation of GLP-1 based drugs, as an adjunct to diet and exercise With this FDA IDE approval...

UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity

Data provides first demonstration of glucose lowering and weight loss potency from pancreas-produced native human GLP-1, highlighting the capacity of pancreatic GLP-1 to provide metabolic control...

Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity

Data provides first demonstration of glucose lowering and weight loss potency from pancreas-produced native human GLP-1, highlighting the capacity of pancreatic GLP-1 to provide metabolic control...

Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials

LEXINGTON, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (“Fractyl Health” or the “Company”), a metabolic therapeutics company focused on pioneering new approaches...

Fractyl Health Announces Pricing of Initial Public Offering

LEXINGTON, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Fractyl Health (Nasdaq: GUTS), a metabolic therapeutics company focused on pioneering new approaches for the treatment of type 2 diabetes...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.172.603369065856.536.886.021425736.51281075CS
40.9115.71675302255.797.845.752504537.09352405CS
12-7.05-51.272727272713.7514.55.753753918.38496879CS
26-7.05-51.272727272713.7514.55.753753918.38496879CS
52-7.05-51.272727272713.7514.55.753753918.38496879CS
156-7.05-51.272727272713.7514.55.753753918.38496879CS
260-7.05-51.272727272713.7514.55.753753918.38496879CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BDRXBiodexa Pharmaceuticals PLC
$ 1.3254
(82.86%)
70.82M
IBRXImmunityBio Inc
$ 7.35
(43.84%)
40.28M
AGENAgenus Inc
$ 11.685
(40.78%)
3.37M
ULHUniversal Logistics Holdings Inc
$ 45.63
(38.74%)
484.22k
NIVFNewGenIvf Group Ltd
$ 1.77
(36.15%)
57.78M
MFImF International Ltd
$ 2.3153
(-77.82%)
21.23M
NWGLNature Wood Group Ltd
$ 5.05
(-70.03%)
2.48M
ICLKiClick Interactive Asia Group Ltd
$ 1.21
(-52.17%)
719.95k
NUWENewellis Inc
$ 0.1695
(-41.35%)
18.46M
SGBXSafe and Green Holdings Corporation
$ 0.1469
(-32.92%)
8.39M
PEGYPineapple Energy Inc
$ 0.065499
(26.20%)
325.57M
SQQQProShares UltraPro Short QQQ
$ 11.43
(-4.75%)
137.28M
INTCIntel Corporation
$ 31.88
(-9.20%)
119.84M
TSLATesla Inc
$ 168.29
(-1.11%)
109.84M
SOFISoFi Technologies Inc
$ 7.87
(3.69%)
88.63M

Your Recent History

Delayed Upgrade Clock